Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6392Neoplasms 408Ovarian Neoplasms 308Triple Negative Breast Neoplasms 286Prostatic Neoplasms 280Lung Neoplasms 271Colorectal Neoplasms 255Neoplasm Metastasis 254Carcinoma, Non-Small-Cell Lung 221Breast Neoplasms, Male 201Colonic Neoplasms 168Motor Activity 166Pancreatic Neoplasms 164Melanoma 157Carcinoma, Intraductal, Noninfiltrating 139Stomach Neoplasms 128Uterine Cervical Neoplasms 127Head and Neck Neoplasms 124Fatigue 104Breast Carcinoma In Situ 103Carcinoma, Ovarian Epithelial 98Endometrial Neoplasms 96Lymphedema 95Carcinoma, Renal Cell 94Urinary Bladder Neoplasms 93Pain 90Sarcoma 89Small Cell Lung Carcinoma 85Lymphoma 83Esophageal Neoplasms 81

Interventions

apatinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Triple-Negative Breast Cancer × Breast × Clear all
NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Fudan University

Phase 2 Completed
66 enrolled
Breast

Advanced Triple-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡